Palvella Therapeutics, Inc (PVLA) - Net Assets
Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has net assets worth $232.31 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($263.76 Million) and total liabilities ($31.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PVLA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $232.31 Million |
| % of Total Assets | 88.08% |
| Annual Growth Rate | -2.04% |
| 5-Year Change | -44.87% |
| 10-Year Change | N/A |
| Growth Volatility | 85.69 |
Palvella Therapeutics, Inc - Net Assets Trend (2020–2025)
This chart illustrates how Palvella Therapeutics, Inc's net assets have evolved over time, based on quarterly financial data. See Palvella Therapeutics, Inc (PVLA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Palvella Therapeutics, Inc (2020–2025)
The table below shows the annual net assets of Palvella Therapeutics, Inc from 2020 to 2025. For live valuation and market cap data, see Palvella Therapeutics, Inc (PVLA) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.98 Million | -55.30% |
| 2024-12-31 | $62.61 Million | +1713.58% |
| 2023-12-31 | $-3.88 Million | +83.26% |
| 2022-12-31 | $-23.17 Million | -145.66% |
| 2021-12-31 | $50.76 Million | +63.58% |
| 2020-12-31 | $31.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Palvella Therapeutics, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7595600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.04% |
| Other Comprehensive Income | $83.00K | 0.30% |
| Other Components | $163.34 Million | 583.70% |
| Total Equity | $27.98 Million | 100.00% |
Palvella Therapeutics, Inc Competitors by Market Cap
The table below lists competitors of Palvella Therapeutics, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Wanma Co Ltd
SHE:002276
|
$1.62 Billion |
|
Astra Microwave Products Limited
NSE:ASTRAMICRO
|
$1.62 Billion |
|
Lanzhou LS Heavy Equipment Co
SHG:603169
|
$1.62 Billion |
|
Lao Feng Xiang Co Ltd A
SHG:600612
|
$1.62 Billion |
|
nCino Inc
NASDAQ:NCNO
|
$1.61 Billion |
|
GIMV NV
BR:GIMB
|
$1.61 Billion |
|
S&T Bancorp Inc
NASDAQ:STBA
|
$1.61 Billion |
|
E-Mart
KO:139480
|
$1.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Palvella Therapeutics, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 62,607,000 to 27,983,000, a change of -34,624,000 (-55.3%).
- Net loss of 41,715,000 reduced equity.
- Other comprehensive income increased equity by 80,000.
- Other factors increased equity by 7,011,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-41.72 Million | -149.07% |
| Other Comprehensive Income | $80.00K | +0.29% |
| Other Changes | $7.01 Million | +25.05% |
| Total Change | $- | -55.30% |
Book Value vs Market Value Analysis
This analysis compares Palvella Therapeutics, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 45.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.47x to 45.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $45.56 | $112.63 | x |
| 2021-12-31 | $62.91 | $112.63 | x |
| 2022-12-31 | $-24.91 | $112.63 | x |
| 2023-12-31 | $-3.06 | $112.63 | x |
| 2024-12-31 | $28.13 | $112.63 | x |
| 2025-12-31 | $2.49 | $112.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Palvella Therapeutics, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -149.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.13x
- Recent ROE (-149.07%) is below the historical average (-64.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -119.99% | -126.97% | 0.28x | 3.38x | $-40.33 Million |
| 2021 | -90.12% | -145.58% | 0.20x | 3.03x | $-50.81 Million |
| 2022 | 0.00% | -128.47% | 1.57x | 0.00x | $-30.96 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $19.08 Million |
| 2024 | -27.85% | 0.00% | 0.00x | 1.41x | $-23.69 Million |
| 2025 | -149.07% | 0.00% | 0.00x | 2.13x | $-44.51 Million |
Industry Comparison
This section compares Palvella Therapeutics, Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Palvella Therapeutics, Inc (PVLA) | $232.31 Million | -119.99% | 0.14x | $1.62 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more